SNU-0039 | CAS# 1018946-38-7 | Anti-Alzheimer's Agent

MedKoo Cat#: 564983 | Name: SNU-0039

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SNU-0039, also known as DWK-1339 and MDR-1339, is an inhibitor of β-amyloid protein aggregation as an anti-Alzheimer's agent.

Chemical Structure

SNU-0039

CAS#1018946-38-7

Theoretical Analysis

MedKoo Cat#: 564983

Name: SNU-0039

CAS#: 1018946-38-7

Chemical Formula: C20H22O4

Exact Mass: 326.1518

Molecular Weight: 326.39

Elemental Analysis: C, 73.60; H, 6.79; O, 19.61

Price and Availability

Size	Price	Availability
200mg	USD 2,650.00	2 Weeks
500mg	USD 3,650.00	2 Weeks
1g	USD 4,650.00	2 Weeks
2g	USD 6,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SNU0039; SNU 0039; SNU-0039; DWK1339; DWK 1339; DWK-1339; MDR-1339; MDR 1339; MDR1339

IUPAC/Chemical Name

2-(3,4-Dimethoxyphenyl)-5-(3-methoxypropyl) benzofuran

InChi Key

CUEPJIGXQLIOIK-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H22O4/c1-21-10-4-5-14-6-8-17-16(11-14)13-19(24-17)15-7-9-18(22-2)20(12-15)23-3/h6-9,11-13H,4-5,10H2,1-3H3

SMILES Code

COCCCC1=CC=C(OC(C2=CC=C(OC)C(OC)=C2)=C3)C3=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SNU-0039 is a blood-brain-barrier-permeable Aβ-aggregation inhibitor.

In vitro activity:

To be determined

In vivo activity:

SNU-0039 may offer an alternative treatment for Alzheimer’s disease (AD). SNU-0039 restored cellular viability from Aβ-induced cytotoxicity but also improved the learning and memory function of AD model mice by reducing the Aβ aggregates in the brains. Reference: J Med Chem. 2018 Jan 11;61(1):396-402. https://pubmed.ncbi.nlm.nih.gov/29161514/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	91.91
	DMSO	30.0	91.91
	Ethanol	2.0	6.13

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 326.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Son JH, Jeong YS, Lee JH, Kim MS, Lee KR, Shim CK, Kim YH, Chung SJ. Identification of metabolites of MDR-1339, an inhibitor of β-amyloid protein aggregation, and kinetic characterization of the major metabolites in rats. J Pharm Biomed Anal. 2018 Mar 20;151:61-70. doi: 10.1016/j.jpba.2017.12.060. Epub 2018 Jan 3. PMID: 29306735. 2. Ha HJ, Kang DW, Kim HM, Kang JM, Ann J, Hyun HJ, Lee JH, Kim SH, Kim H, Choi K, Hong HS, Kim Y, Jo DG, Lee J, Lee J. Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease. J Med Chem. 2018 Jan 11;61(1):396-402. doi: 10.1021/acs.jmedchem.7b00844. Epub 2017 Dec 6. PMID: 29161514.

In vitro protocol:

To be determined

In vivo protocol:

1. Lee KR, Chae YJ, Maeng HJ, Lee J, Kim DD, Chong S, Shim CK, Chung SJ. Physiologically based pharmacokinetic modeling of SNU-0039, an anti-Alzheimer's agent, in rats. J Pharmacokinet Pharmacodyn. 2011 Oct;38(5):637-51. doi: 10.1007/s10928-011-9212-6. Epub 2011 Aug 25. PubMed PMID: 21866408. 2. Son JH, Jeong YS, Lee JH, Kim MS, Lee KR, Shim CK, Kim YH, Chung SJ. Identification of metabolites of MDR-1339, an inhibitor of β-amyloid protein aggregation, and kinetic characterization of the major metabolites in rats. J Pharm Biomed Anal. 2018 Mar 20;151:61-70. doi: 10.1016/j.jpba.2017.12.060. Epub 2018 Jan 3. PMID: 29306735. 3. Ha HJ, Kang DW, Kim HM, Kang JM, Ann J, Hyun HJ, Lee JH, Kim SH, Kim H, Choi K, Hong HS, Kim Y, Jo DG, Lee J, Lee J. Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease. J Med Chem. 2018 Jan 11;61(1):396-402. doi: 10.1021/acs.jmedchem.7b00844. Epub 2017 Dec 6. PMID: 29161514.